ReviewFrontiers in immunology2026
Acyl-CoA thioesterases and their derived lipid mediators: linking Acyl-CoA metabolic reprogramming to the tumor microenvironment.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic reprogramming in tumors is a fundamental mechanism by which tumor cells adapt to proliferative stress and evade immune surveillance. In recent years, the regulatory role of lipid metabolism-particularly acyl-CoA metabolism-within the tumor microenvironment has garnered increasing attention. As a central hub of lipid metabolism, acyl-CoA homeostasis directly determines cellular energy status, membrane lipid composition, and signal output. The acyl-CoA thioesterase (ACOT) family regulates intracellular homeostasis of free fatty acids (FFAs) and acyl-CoA by hydrolyzing the thioester bond of acyl-CoA, thereby influencing membrane lipid composition, ferroptosis sensitivity, and immune cell function, and consequently promoting tumor progression, drug resistance, and microenvironmental remodeling. In this context, this review systematically summarizes the structural and functional characteristics of the ACOT family, elucidates the regulatory networks of its derived lipid mediators in tumors, and describes its effects on tumor metabolism and the microenvironment through interactions with other metabolic enzymes. This review aims to reveal the pivotal role of the ACOT family in the tumor metabolism-immunity network, update our understanding of its complex roles in tumors, and provide theoretical insights and future research directions for its potential as a drug target and for overcoming treatment resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.